Expression and Clinical Significance of Microrna-129 in Advanced Gastric Cancer
刘娟,史伟峰,徐斌,郑晓,王琦,卢斌峰,鞠景芳,吴昌平,蒋敬庭
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2014.03.015
2014-01-01
Abstract:Objective To explore the microRNA (miR)-129 expression and its clinical significance in advanced gastric cancer,to evaluate the effectiveness of S-1/oxaliplatin vs.doxifluridine/oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in patients with advanced gastric cancer.Methods Total RNAs were extracted from normal and gastric tumor formalinfixed,paraffin embedded (FFPE) specimens.miR-129 expression was quantified using real-time quantitative polymerase chain reaction (real-time PCR) analysis.The correlation between the expression levels of miR-129 with clinical characteristics was analyzed by using chi-square test.Overall survival (OS) in patients with clinicopathological characteristics was analyzed using Kaplan-Meier and Log-rank test.The Cox proportional hazards model was performed to estimate Hazard risk (HR) with 95％ confidence interval (CI) of the linking strength between the different clinical characteristics,the expression of miR-129,and death risk.Results The expression levels of miR-129 were significantly up-regulated in gastric tumors compared to normal gastric tissues (P ＜ 0.01),and were significantly correlated with the previous treatment (P ＜ 0.05),but not with gender,age,stage,tumor size and histological type by using Chi-square test.After two-course treatment,therapeutic effectiveness was significantly correlated with OS (P ＜ 0.05),and Kaplan-Meier survival analysis revealed that the median survival time in patients with PR,SD and PD was 8.41 (5.29-11.52),10.16 (7.19-13.14) and 5.10 (3.11-7.08) months respectively.The up-regulation of the miR-129 expression was closely associated with shorter OS.The median OS in patient with low expression of miR-129 was 8.74 (6.71-10.77) months.In contrast,the median OS was only 6.27 (5.17-7.37)months in patients with the high expression of miR-129 (P ＜ 0.05).The results of Cox model showed that the HR of patients SD,and PD was 0.95 (95％ CI:0.351-2.562,P ＞0.05) and 6.02 (95％ CI:1.683-21.570,P ＜0.0l) as compared with PR patients.The median survival time in patients with low miR-129expression was significantly prolonged as compared with that in patients with high miR-129 expression [8.74 (6.71-10.77) and 6.27 (5.17-7.37),respectively].The HR for death risk in stomach carcinoma patients with high miR-129 expression was 2.77 times higher than in those with low miR-129 expression (95％ CI:1.12-6.87,P ＜ 0.05).Conclusion Abnormal expression of miR-129 has been implicated in gastric cancer,and the expression level of miR-129 was closely associated with prognosis of advanced gastric cancer patients.miR-129 holds great potential as a prognostic biomarker and a valuable indicator of chemotherapy regimen in gastric cancer.